Erschienen in:
17.05.2019 | Research Letter
Adrenal insufficiency treated with conventional hydrocortisone leads to elevated levels of Interleukin-6: a pilot study
verfasst von:
Amir-Hossein Rahvar, Martin Riesel, Tobias Graf, Birgit Harbeck
Erschienen in:
Endocrine
|
Ausgabe 3/2019
Einloggen, um Zugang zu erhalten
Excerpt
Adrenal insufficiency is a rare disease with an estimated prevalence of 100–126 cases per million for primary adrenal insufficiency (PAI) and 450 cases per million for secondary/tertiary adrenal insufficiency (SAI/TAI) [
1,
2]. Glucocorticoid replacement therapy (GRT) is the gold standard and only viable treatment for AI [
3]. The present guideline on PAI recommends the use of hydrocortisone (HC) or prednisolone for GRT [
3]. However, currently used GRT regimens inadequately mimic the physiological rhythm of endogenous cortisol secretion leading to temporary hypercortisolism and hypocortisolism [
4]. The consequences of these conditions are not completely understood but may be associated with deleterious effects on body composition [
5]. In fact, patients with AI on GRT have an increased cardiovascular and cerebrovascular mortality [
6,
7]. …